Old Web
English
Sign In
Acemap
>
authorDetail
>
Fei Kong
Fei Kong
Zhengzhou University
Oncology
Medicine
Internal medicine
Series (stratigraphy)
CHOP
3
Papers
2
Citations
0
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Ibrutinib in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Retrospective Study
2021
Indian Journal of Hematology and Blood Transfusion
Liangliang Ren
Ling Li
Lei Zhang
Xin Li
Xiaorui Fu
Xinhua Wang
Jingjing Wu
Zhenchang Sun
Xiaoyan Feng
Yu Chang
Zhiyuan Zhou
Feifei Nan
Jiaqin Yan
Fei Kong
Mingzhi Zhang
Show All
Source
Cite
Save
Citations (0)
Apatinib, a novel VEGFR-2 tyrosine kinase inhibitor, for relapsed and refractory nasopharyngeal carcinoma: data from an open-label, single-arm, exploratory study.
2020
Investigational New Drugs
Ling Li
Fei Kong
Lei Zhang
Xin Li
Xiaorui Fu
Xinhua Wang
Jingjing Wu
Fangwen Zhang
Liangliang Ren
Mingzhi Zhang
Show All
Source
Cite
Save
Citations (1)
Prognostic analysis of CD5 expression in double-hit diffuse large B-cell lymphoma and effectiveness comparison in patients treated with dose-adjusted EPOCH plus rituximab/R-CHOP regimens
2019
Fangwen Zhang
Ling Li
Lei Zhang
Xin Li
Xiaorui Fu
Xinhua Wang
Jingjing Wu
Zhenchang Sun
Fei Kong
Liangliang Ren
Mingzhi Zhang
Show All
Source
Cite
Save
Citations (1)
1